Therapeutic Solutions International. has filed a patent for a method of treating cognitive dysfunction associated with COVID-19 and other inflammatory conditions. The treatment involves administering nutraceuticals such as green tea extract, nigella sativa, pterostilbene, and sulforaphane to induce the growth of neural progenitor cells and protect cells from inflammatory damage. The patent also claims that these nutraceutical compositions can be used to overcome treatment resistance in currently used antidepressants. GlobalData’s report on Therapeutic Solutions International gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Therapeutic Solutions International, Cancer immunotherapy was a key innovation area identified from patents. Therapeutic Solutions International's grant share as of September 2023 was 11%. Grant share is based on the ratio of number of grants to total number of patents.
The patent filed is for a method of treating cognitive dysfunction associated with covid-19 and inflammatory conditions using a specific combination of nutraceuticals
A recently filed patent (Publication Number: US20230301938A1) describes a method for preventing or reducing cognitive decline in patients suffering from COVID-19 or cognitive disorders triggered by inflammation. The method involves administering a nutraceutical containing pterostilbene, sulforaphane, green tea extract, and nigella sativa.
The patent claims that the method can be effective in preventing or reducing cognitive decline in patients with various cognitive disorders, including delirium, Alzheimer's Disease, multiple sclerosis, stroke, Parkinson's Disease, Huntington's Disease, dementia, frontotemporal dementia, vascular dementia, HIV dementia, COVID-19 associated dementia, Post-Traumatic Stress Disorder, and Rheumatoid Arthritis.
Furthermore, the method can also be used in patients who have undergone surgery or chemotherapy, which are considered inflammatory triggers.
In addition to the nutraceutical, the patent suggests that administering n-acetylcysteine and histone deacetylase inhibitors to the patient may enhance the therapeutic effect. Histone deacetylase inhibitors such as valproic acid, sodium butyrate, istodax, vorinostat, panobinostat, belinostat, trichostatin A, and CCL996 are specifically mentioned as potential options.
The patent also provides a list of surgical procedures that may benefit from this method, including cardiothoracic, orthopaedic, neurological, vascular, plastic & reconstructive, gynaecological, obstetric, urological, general, head & neck, ear, nose & throat (ENT), paediatric, dental, maxillofacial, ophthalmic, pain management, trauma, and minor surgical procedures. Specific examples mentioned include colorectal, hepatobiliary, upper gastro-intestinal surgical procedures, catheterisation, minor skin procedures, minor orthopedic procedures, nerve blocks, endoscopy, and transoesophageal echocardiogram.
It is important to note that this information is based solely on the claims made in the filed patent and does not provide any evidence or clinical data to support the effectiveness of the method. Further research and clinical trials would be necessary to validate these claims and determine the actual efficacy of the described method in preventing or reducing cognitive decline in patients with COVID-19 or inflammatory trigger-related cognitive disorders.
To know more about GlobalData’s detailed insights on Therapeutic Solutions International, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
